Amylyx Pharmaceuticals, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19
	10-K	8-K	10-K	8-K	S-1	S-1/A
Revenues:
Research and development		93.5
Product revenue, net	22.2	22.2
Total revenues [+]	22.2	115.7	0.3	44.0	24.6
Royalties		93.5		44.0	24.6
Products	22.2	22.2
Revenue growth	7700.0%	162.7%	-98.8%
Cost of goods sold	3.0	93.5	0.0	43.8	39.7
Gross profit	19.2	22.2	0.3	0.3	-15.1
Gross margin	86.5%	19.2%	100.0%	0.6%	-61.2%
Selling, general and administrative [+]	127.1	127.1	38.9	38.9	15.1
General and administrative					15.1
Research and development	116.4		44.0
Other operating expenses	-22.9	96.4		44.0	8.9
EBITDA [+]	-200.9		-82.6
EBITDA growth	143.1%	143.5%	111.9%
EBITDA margin	-903.5%	-174.0%	-28995.1%	-187.8%	-158.6%
Depreciation and amortization	0.5		0.1
EBIT [+]	-201.3	-201.3	-82.7	-82.7	-39.0
EBIT growth	143.5%	143.5%	112.0%
EBIT margin	-905.7%	-174.0%	-29013.3%	-187.8%	-158.6%
Interest income	4.3		0.0		0.0
Interest income	4.3		0.0		0.0
Other income (expense), net [+]	-0.6	3.7	-5.3	-5.2	-3.3
Unrealized gain/loss on derivatives					-1.3
Other	-0.6		-0.1		0.3
Pre-tax income	-197.6	-197.6	-87.9	-87.9	-42.3
Income taxes	0.8	0.8	0.0	0.0	0.0
Tax rate			0.0%	0.0%	0.0%
Net income	-198.4	-198.4	-87.9	-87.9	-42.3
Net margin	-892.4%	-171.5%	-30853.0%	-199.7%	-171.9%

Basic EPS [+]	($3.39)	($3.39)	($13.35)	($13.35)	($6.96)
Growth	-74.6%	-74.6%	91.9%
Diluted EPS [+]	($3.39)	($3.39)	($13.35)	($13.35)	($6.96)
Growth	-74.6%	-74.6%	91.9%

Shares outstanding (basic) [+]	58.5	58.5	6.6	6.6	6.1
Growth	788.1%	788.1%	8.4%
Shares outstanding (diluted) [+]	58.5	58.5	6.6	6.6	6.1
Growth	788.1%	788.1%	8.4%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.